Impact of Radical Prostatectomy on Long-Term Oncologic Outcomes in a Matched Cohort of Men with Pathological Node Positive Prostate Cancer Managed by Castration
- PMID: 28130104
- DOI: 10.1016/j.juro.2017.01.063
Impact of Radical Prostatectomy on Long-Term Oncologic Outcomes in a Matched Cohort of Men with Pathological Node Positive Prostate Cancer Managed by Castration
Abstract
Purpose: Long-term data supporting the role of primary tumor resection in node positive prostate cancer are lacking. We evaluated the impact of adding radical retropubic prostatectomy to surgical castration on long-term oncologic outcomes in pathological node positive prostate cancer.
Materials and methods: We identified men who underwent pelvic lymphadenectomy and orchiectomy within 90 days for pathological node positive prostate cancer from 1966 to 1995. Men treated with radical retropubic prostatectomy in addition to orchiectomy were matched 1:1 to men who underwent orchiectomy alone based on age, year of surgery, clinical grade, clinical T stage, number of positive nodes and preoperative serum prostate specific antigen, the latter from 1987 and thereafter. Kaplan-Meier and Cox regression analyses were done to compare cancer specific and overall survival.
Results: The matched cohort included 158 men with 79 in each group. Of men who underwent orchiectomy alone 76 died, including 60 of prostate cancer. Of patients treated with radical retropubic prostatectomy plus orchiectomy 70 died, including 28 of prostate cancer. On Kaplan-Meier analyses prostatectomy plus orchiectomy vs orchiectomy alone was associated with prolonged cancer specific survival (at 20 years 59% vs 18%, log rank p <0.001) and overall survival (at 20 years 22% vs 9%, log rank p <0.001). In Cox models prostatectomy plus orchiectomy vs orchiectomy alone was associated with improved cancer specific survival (HR 0.28, 95% CI 0.17-0.46, p <0.001) and overall survival (HR 0.48, 95% CI 0.34-0.66, p <0.001). Findings were similar in the subset with available preoperative prostate specific antigen values.
Conclusions: With lifelong followup in nearly the entire cohort, this study demonstrates that adding radical retropubic prostatectomy to surgical castration for pathological node positive prostate cancer is associated with improved cancer specific and overall survival. When technically feasible in well selected patients, aggressive locoregional resection should be considered for node positive prostate cancer as part of a multimodal approach.
Keywords: castration; mortality; neoplasm metastasis; prostatectomy; prostatic neoplasms.
Copyright © 2017 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Comment in
-
Re: Impact of Radical Prostatectomy on Long-term Oncologic Outcomes in a Matched Cohort of Men with Pathological Node Positive Prostate Cancer Managed by Castration.Eur Urol. 2018 Jan;73(1):140. doi: 10.1016/j.eururo.2017.09.034. Epub 2017 Oct 18. Eur Urol. 2018. PMID: 29054500 No abstract available.
Similar articles
-
Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison.J Urol. 1999 Apr;161(4):1223-7; discussion 1227-8. J Urol. 1999. PMID: 10081874 Clinical Trial.
-
Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.BJU Int. 2011 Jun;107(11):1755-61. doi: 10.1111/j.1464-410X.2010.09730.x. Epub 2010 Oct 13. BJU Int. 2011. PMID: 20942833
-
Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era.Urol Oncol. 2013 Nov;31(8):1441-7. doi: 10.1016/j.urolonc.2012.03.006. Epub 2012 Apr 18. Urol Oncol. 2013. PMID: 22516714
-
No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.Urology. 2004 Mar;63(3):528-31. doi: 10.1016/j.urology.2003.09.064. Urology. 2004. PMID: 15028451 Review.
-
Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation.J Urol. 1998 Feb;159(2):357-64. doi: 10.1016/s0022-5347(01)63917-x. J Urol. 1998. PMID: 9649239 Review.
Cited by
-
Cytoreductive prostatectomy improves survival outcomes in patients with oligometastases: a systematic meta-analysis.World J Surg Oncol. 2022 Aug 9;20(1):255. doi: 10.1186/s12957-022-02715-x. World J Surg Oncol. 2022. PMID: 35945562 Free PMC article.
-
Narrative review of management strategies and outcomes in node-positive prostate cancer.Transl Androl Urol. 2021 Jul;10(7):3176-3187. doi: 10.21037/tau-20-1031. Transl Androl Urol. 2021. PMID: 34430420 Free PMC article. Review.
-
Evaluating the effectiveness of cytoreductive surgery in oligometastatic prostate cancer: insights from quantitative analysis and retrospective cohort studies.Int J Surg. 2025 Jan 1;111(1):122-134. doi: 10.1097/JS9.0000000000001968. Int J Surg. 2025. PMID: 39007913 Free PMC article.
-
Can local treatment prolong the sensitivity of metastatic prostate cancer to androgen deprivation or even prevent castration resistance?World J Urol. 2021 Sep;39(9):3231-3237. doi: 10.1007/s00345-020-03568-3. Epub 2021 Jan 27. World J Urol. 2021. PMID: 33502558 Free PMC article.
-
[Trivialization of prostate cancer? : Stage shift and possible causes].Urologe A. 2019 Dec;58(12):1461-1468. doi: 10.1007/s00120-019-01039-1. Urologe A. 2019. PMID: 31531694 German.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical